Catalyst
Slingshot members are tracking this event:
Celgene discontinues GED-0301 (mongersen) Inflammatory Bowel Disease Program's phase III REVOLVE trial (CD-002) and the extension trial (SUSTAIN, CD-004)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CELG |
|
|
||||
Additional Information
At this time, the phase III DEFINE trial (CD-003) in Crohn's disease will not be initiated. Celgene is waiting to review the full dataset from the phase II trial with GED-0301 in ulcerative colitis (UC) to determine next steps.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 19, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ged-0301, Mongersen, Inflammatory Bowel Disease, Revolve Trial, Cd-002, Sustain, Cd-004
